Ubiquigent is dedicated to providing a range of state-of-the-art Drug Discovery Services to support the rapidly growing academic and commercial drug discovery interests in this field.Novel Compound LibrariesDUBtarget™-001 - Ubiquigent Ltd and The Drug Discovery Unit at the University of Dundee have jointly developed the first commercially available compound library designed to target deubiquitylase (DUB) enzymes, DUBtarget™-001. The library has been screened against USP2 (a key target opportunity in cancer) employing our DUBprofiler™ – DUB affinity and selectivity profiling – platform. These data, as well as the physical library, are now available to access along with the option to screen the library against any of the other 40 DUB enzymes available as part of DUBprofiler to help inform starting points for drug development programmes. We are now offering parties access to the library, associated data and further characterisation of the compound set using DUBprofiler to support their ubiquitin-system drug discovery programmes.Regardless of whether you’re interested in screening for a novel ubiquitin deubiquitylase enzyme (DUB) inhibitor, a modulator of a ubiquitin ligase (E3s) or wish to investigate any other part of the ubiquitin system, we have the assays and capabilities available to support your research programmes.Drug Discovery ServicesDUBprofiler™ is one of our standard services designed to help you quickly identify DUB inhibitors. DUBprofiler is available in two formats; you can choose to screen compounds at either single or multiple concentrations in either high-throughput (HT) or non-HT modes allowing studies to be run in the most efficient way regardless of compound numbers.REDOXprofiler™ is another standard service. Certain compounds may generate Reactive Oxygen Species (ROS) such as hydrogen peroxide (H2O2) or superoxide (O2–), particularly in the presence of reducing agents including dithiothreitol (DTT). In screening campaigns such ROS generating or redox cycling compounds (RCCs) can cause false positive inhibition of enzymes that utilise a catalytic cysteine. This occurs through the oxidation of that cysteine to a reversible sulphenic acid (SOH) or an irreversible sulphinic (SO2H) or sulphonic (SO3H) acid. Ubiquigent has developed two complementary assays that may be used to identify RCCs - REDOXprofiler™-Resazurin and REDOXprofiler™-Cat/SOD.Our IDOL assay is an example of a standard assay that offers the ability to screen compounds for activity at a specific E3 ligase. IDOL has recently been identified as a target of significant interest in Alzheimer’s disease and in the regulation and turnover of the LDL receptor (LDLR) in lipid homeostasis. Our IDOL assay is also available in multiple formats depending on your requirements.We offer cell based assays to support your target and biomarker discovery and validation projects including assays which may utilise Horizon knock out cell lines and associated CRISPR/Cas9 gene editing technologies. We are also developing DUBprofiler-Cell™, an assay to determine the in-cell DUB target engagement profile of molecules arising from your drug discovery programmes. As part of this latter service we will also be able to report to you the DUBome profile (expressed and detectable DUBs) of a cell line of choice. This DUBome may be determined and compared between cell lines which may be treated or untreated with cell signalling activating ligands and/or other stimuli and/or may carry a genetically defined mutation (see Horizon technology above) in support of target identification and validation objectives.Other assays may also be developed utilising technology platforms such as those available through our collaboration with CAST:
- Cell imaging
- Flow cytometry
- Mass spectrometry
Specialised services such as high sensitivity surface plasmon resonance for characterising protein-protein and protein-small molecule interactions are also accessible by Ubiquigent.Our Custom Drug Discovery Services capability is where we develop new assays on a case-by-case basis in response to our client’s requests. Once developed we can run these assays on your behalf, transfer them to your lab or use a combination of the two approaches.For further details on any of our services, follow the links on the left or Contact us directly to discuss your requirements.
Ubiquigent Limited is a specialist developer and supplier of Drug Discovery Services, high quality Research Tools and Chemistryto the life science research community worldwide.Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems.The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The Company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the Company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.